# OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

> **NCT05333328** · PHASE4 · RECRUITING · sponsor: **Gangnam Severance Hospital** · enrollment: 418 (estimated)

## Conditions studied

- Breast Cancer
- Estrogen Receptor Positive Tumor
- HER2-negative Breast Cancer
- Premenopausal Breast Cancer
- Node-positive Breast Cancer

## Interventions

- **DRUG:** Ovarian function suppression with endocrine treatments

## Key facts

- **NCT ID:** NCT05333328
- **Lead sponsor:** Gangnam Severance Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-06
- **Primary completion:** 2031-01
- **Final completion:** 2033-01
- **Target enrollment:** 418 (ESTIMATED)
- **Last updated:** 2025-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05333328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05333328, "OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05333328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*